Mucosal vaccination with hemagglutinin stalk provides broad protection against influenza virus subtypes in mice
Journal of Clinical Investigation · 16.11.2026 · 136 (22)
DOI: 10.1172/jci203675 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 16.11.2026. Verfasst von Weizhong Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology, Virginia-Maryland College of Veterinary Medicine, University of Maryland, College Park, Maryland, USA. Hauptthemen laut MEDLINE: Influenza Vaccines, Orthomyxoviridae Infections, Hemagglutinin Glycoproteins, Influenza Virus, Immunity, Mucosal. Die Arbeit nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, USDA NIFA A1181 Biosecurity grant.
Abstract (Originalsprache)
Influenza viruses continually evolve through antigenic drift and shift, spreading via respiratory droplets and aerosols. Developing a universal nasal vaccine is essential for preventing seasonal and pandemic infections by inducing long-lasting immunity in the respiratory tract. The neonatal Fc receptor (FcRn) transfers IgG Abs across the epithelial barrier. This study investigates whether the i.n. delivery of the conserved Stalk antigen of HA, utilizing the FcRn, can stimulate protective immune responses against various influenza virus subtypes. We engineered a monomeric IgG Fc fused to a modified HA Stalk in its prefusion form. Mice i.n. immunized with Stalk-Fc exhibited significant protection against infections from H1N1, H5N1, H6N2, and H9N2 compared with groups of control mice. The immunized mice produced long-lasting HA Stalk–specific IgA and IgG Abs in nasal washes, bronchoalveolar lavage, and blood, along with tissue-resident memory T cells in the lungs and long-lived plasma cells in the bone marrow. This led to notably lower viral replication in the nasal turbinate and lungs. The Stalk-specific Abs demonstrated strong cross-reactivity against different influenza subtypes through neutralization, Ab- or complement-dependent cellular cytotoxicity, or phagocytosis. These results indicate that FcRn efficiently transports HA Stalk-Fc across the respiratory epithelial barrier, supporting the development of a universal influenza nasal vaccine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Immunology, Virginia-Maryland College of Veterinary Medicine, University of Maryland, College Park, Maryland, USA.
- Animal Parasitic Diseases Laboratory, Agricultural Research Service, United States Department of Agriculture, Beltsville, Maryland, USA.
- Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Förderung
- National Institute of Allergy and Infectious Diseases
- USDA NIFA A1181 Biosecurity grant
Zitieren
APA
Li, W., Rajendrakumar, A. M., Miao, Z., Dhakal, B., Domrachev, B. M., Wang, T., Kan, Q., Wan, Q., Wan, H., Tuo, W., Krammer, F., Ye, Z., & Zhu, X. (2026). Mucosal vaccination with hemagglutinin stalk provides broad protection against influenza virus subtypes in mice. Journal of Clinical Investigation, 136(22). https://doi.org/10.1172/jci203675
Vancouver
Li W, Rajendrakumar AM, Miao Z, Dhakal B, Domrachev BM, Wang T, et al. Mucosal vaccination with hemagglutinin stalk provides broad protection against influenza virus subtypes in mice. Journal of Clinical Investigation. 2026;136(22). doi:10.1172/jci203675
BibTeX
@article{Li2026,
author = {Li, Weizhong and Rajendrakumar, Arunraj M and Miao, ZiZhen and Dhakal, Bibek and Domrachev, Bogdan M and Wang, Tao and Kan, Qiuqi and Wan, Qiaofeng and Wan, Hongquan and Tuo, Wenbin and Krammer, Florian and Ye, Zhiping and Zhu, Xiaoping},
title = {Mucosal vaccination with hemagglutinin stalk provides broad protection against influenza virus subtypes in mice},
journal = {Journal of Clinical Investigation},
year = {2026},
volume = {136},
number = {22},
doi = {10.1172/jci203675}
}
EUVIMED